News|Articles|September 30, 2025

Key pediatric FDA decisions to watch for in Q4 2025

Fact checked by: Morgan Ebert, Executive Editor

From another potential treatment for pediatric atopic dermatitis, to STI therapy for uncomplicated urogenital gonorrhea, take a look ahead at key PDUFA dates in Q4.

The fourth quarter of 2025 has all but arrived, and with it, several key potential approvals from the FDA for the pediatric population. From treatments for achondroplasia to atopic dermatitis (AD) in children 2 to 5 years, these potential FDA decisions could influence treatment landscapes for children and teenagers.